Literature DB >> 3409485

Prenatal and postnatal hydralazine treatment does not prevent renal vessel wall thickening in SHR despite the absence of hypertension.

J S Smeda1, R M Lee, J B Forrest.   

Abstract

Previous studies in our laboratory have shown that the renal blood vessels of 21-week-old Wistar-Kyoto spontaneously hypertensive rats exhibited thicker vascular walls than age matched Wistar-Kyoto normotensive rats. Morphometric analysis of the relaxed renovasculature revealed an increase in the cross-sectional area of the media, which in most cases was associated with an increase in the number of smooth muscle cell layers. To test if these structural changes occur in the absence of raised blood pressure, hydralazine was administered to spontaneously hypertensive rats and normotensive controls prior to and during pregnancy (100 ml/l drinking water), and to the newborn males up to 21 weeks of age (16.9 mg/kg/day by gavage until weaning followed by 100 mg/l in the drinking water). Treated animals were compared with untreated rats. Treatment prevented hypertension development in spontaneously hypertensive rats but did not alter the structural changes found in untreated animals with hypertension. At 21 weeks of age, hydralazine-treated spontaneously hypertensive rats had similar wall-to-lumen area ratios, medial cross-sectional areas and numbers of medial smooth muscle layers as untreated hypertensive rats while these parameters were greater in treated and untreated spontaneously hypertensive rats than in either treated or untreated normotensive controls. Withdrawal of hydralazine from 26-week-old spontaneously hypertensive rats that had been treated in utero and postnatally and had normal blood pressures throughout life resulted in the rapid onset of hypertension. Our results show that renal vascular wall thickening in spontaneously hypertensive rats occurs in the absence of high blood pressure and therefore is not a secondary effect of raised blood pressure.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3409485     DOI: 10.1161/01.res.63.3.534

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  8 in total

Review 1.  Molecular aspects of pathological processes in the artery wall.

Authors:  J W van Neck; H P Bloemers
Journal:  Mol Biol Rep       Date:  1992-11       Impact factor: 2.316

Review 2.  Changes to the vascular system resulting from hypertension and their effects on response to therapy.

Authors:  M J Mulvany
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 3.  Vascular structural and functional changes: their association with causality in hypertension: models, remodeling and relevance.

Authors:  Robert Mkw Lee; Jeffrey G Dickhout; Shaun L Sandow
Journal:  Hypertens Res       Date:  2016-10-27       Impact factor: 3.872

4.  Influence of neonatal sympathectomy on proximal renal resistance artery function in spontaneously hypertensive rats.

Authors:  Olaf Grisk; Ulrike Lother; Gert Gabriëls; Rainer Rettig
Journal:  Pflugers Arch       Date:  2004-10-12       Impact factor: 3.657

Review 5.  Cellular mediators of renal vascular dysfunction in hypertension.

Authors:  Bharathy Ponnuchamy; Raouf A Khalil
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-02-18       Impact factor: 3.619

6.  Differences in autonomic innervation to the vertebrobasilar arteries in spontaneously hypertensive and Wistar rats.

Authors:  Eva V L Roloff; Dawid Walas; Davi J A Moraes; Sergey Kasparov; Julian F R Paton
Journal:  J Physiol       Date:  2018-07-19       Impact factor: 5.182

7.  Downregulation of alpha7 nicotinic acetylcholine receptor in two-kidney one-clip hypertensive rats.

Authors:  Ji-Kuai Chen; Ting Zhao; Min Ni; Dong-Jie Li; Xia Tao; Fu-Ming Shen
Journal:  BMC Cardiovasc Disord       Date:  2012-06-08       Impact factor: 2.298

Review 8.  Neurogenic hypertension and elevated vertebrobasilar arterial resistance: is there a causative link?

Authors:  Matthew J Cates; C John Dickinson; Emma C J Hart; Julian F R Paton
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.